Is Ginkgo Bioworks Stock a Good Investment?
Ginkgo Bioworks Investment Advice | DNA |
- Examine Ginkgo Bioworks' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Ginkgo Bioworks' leadership team and their track record. Good management can help Ginkgo Bioworks navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Ginkgo Bioworks' business and its evolving consumer preferences.
- Compare Ginkgo Bioworks' performance and market position to its competitors. Analyze how Ginkgo Bioworks is positioned in terms of product offerings, innovation, and market share.
- Check if Ginkgo Bioworks pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Ginkgo Bioworks' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Ginkgo Bioworks Holdings stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Ginkgo Bioworks Holdings is a good investment.
Sell | Buy |
Strong Buy
Market Performance | Very Weak | Details | |
Volatility | Unstable | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Hold | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Ginkgo Bioworks Stock
Researching Ginkgo Bioworks' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 69.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.52. Some equities with similar Price to Book (P/B) outperform the market in the long run. Ginkgo Bioworks Holdings recorded a loss per share of 12.89. The entity had not issued any dividends in recent years. The firm had 1:40 split on the 20th of August 2024.
To determine if Ginkgo Bioworks is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Ginkgo Bioworks' research are outlined below:
Ginkgo Bioworks had very high historical volatility over the last 90 days | |
Ginkgo Bioworks has high likelihood to experience some financial distress in the next 2 years | |
The company reported the last year's revenue of 251.46 M. Reported Net Loss for the year was (892.87 M) with profit before taxes, overhead, and interest of 273.49 M. | |
Ginkgo Bioworks Holdings has about 1.32 B in cash with (295.5 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.84. | |
Ginkgo Bioworks has a poor financial position based on the latest SEC disclosures | |
Roughly 69.0% of the company shares are held by institutions such as insurance companies | |
Latest headline from huffpost.com: Man Cleared In Teens Cold-Case Death After Passing Lie Detector Is Now Named A Suspect |
Ginkgo Bioworks Quarterly Gross Profit |
|
Ginkgo Bioworks uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Ginkgo Bioworks Holdings. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Ginkgo Bioworks' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
6th of March 2024 Upcoming Quarterly Report | View | |
8th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
6th of March 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Ginkgo Bioworks' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Ginkgo Bioworks' investors have experienced.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2024-02-29 | 2023-12-31 | -0.1 | -0.11 | -0.01 | 10 | ||
2023-08-09 | 2023-06-30 | -0.08 | -0.09 | -0.01 | 12 | ||
2023-05-10 | 2023-03-31 | -0.09 | -0.11 | -0.02 | 22 | ||
2021-11-15 | 2021-09-30 | -0.04 | -0.06 | -0.02 | 50 | ||
2023-11-08 | 2023-09-30 | -0.09 | -0.16 | -0.07 | 77 | ||
2022-11-14 | 2022-09-30 | -0.3 | -0.41 | -0.11 | 36 | ||
2023-03-01 | 2022-12-31 | -0.21 | -0.09 | 0.12 | 57 | ||
2022-05-16 | 2022-03-31 | -0.03 | -0.3 | -0.27 | 900 |
Know Ginkgo Bioworks' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Ginkgo Bioworks is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Ginkgo Bioworks Holdings backward and forwards among themselves. Ginkgo Bioworks' institutional investor refers to the entity that pools money to purchase Ginkgo Bioworks' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Viking Global Investors Lp | 2024-09-30 | 3.6 M | Baillie Gifford & Co Limited. | 2024-09-30 | 3.4 M | T. Rowe Price Associates, Inc. | 2024-06-30 | 3 M | Salem Investment Counselors Inc | 2024-06-30 | 2.8 M | Bank Of America Corp | 2024-06-30 | 2.7 M | Vanguard Group Inc | 2024-09-30 | 2.6 M | Millennium Management Llc | 2024-06-30 | 2.2 M | Susquehanna International Group, Llp | 2024-06-30 | 2 M | Anchorage Advisors, Llc | 2024-09-30 | 1.7 M | Blackrock Inc | 2024-06-30 | 42 M | Two Sigma Advisers, Llc | 2024-06-30 | 31.4 M |
Ginkgo Bioworks' market capitalization trends
The company currently falls under 'Small-Cap' category with a total capitalization of 412.7 M.Market Cap |
|
Ginkgo Bioworks' profitablity analysis
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.58) | (0.61) | |
Return On Capital Employed | (0.58) | (0.60) | |
Return On Assets | (0.54) | (0.56) | |
Return On Equity | (0.81) | (0.85) |
Determining Ginkgo Bioworks' profitability involves analyzing its financial statements and using various financial metrics to determine if Ginkgo Bioworks is a good buy. For example, gross profit margin measures Ginkgo Bioworks' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Ginkgo Bioworks' profitability and make more informed investment decisions.
Please note, the presentation of Ginkgo Bioworks' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Ginkgo Bioworks' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Ginkgo Bioworks' management manipulating its earnings.
Evaluate Ginkgo Bioworks' management efficiency
Ginkgo Bioworks Holdings has Return on Asset of (0.2092) % which means that on every $100 spent on assets, it lost $0.2092. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.6351) %, meaning that it generated no profit with money invested by stockholders. Ginkgo Bioworks' management efficiency ratios could be used to measure how well Ginkgo Bioworks manages its routine affairs as well as how well it operates its assets and liabilities. As of November 24, 2024, Return On Tangible Assets is expected to decline to -0.61. In addition to that, Return On Capital Employed is expected to decline to -0.6. At present, Ginkgo Bioworks' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 107.1 M, whereas Net Tangible Assets are forecasted to decline to about 1.1 B.Last Reported | Projected for Next Year | ||
Book Value Per Share | 22.57 | 17.71 | |
Tangible Book Value Per Share | 19.86 | 16.42 | |
Enterprise Value Over EBITDA | (3.15) | (3.30) | |
Price Book Value Ratio | 3.00 | 2.85 | |
Enterprise Value Multiple | (3.15) | (3.30) | |
Price Fair Value | 3.00 | 2.85 | |
Enterprise Value | 2.6 B | 2.5 B |
Leadership effectiveness at Ginkgo Bioworks Holdings is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Beta 1.098 |
Basic technical analysis of Ginkgo Stock
As of the 24th of November, Ginkgo Bioworks retains the Market Risk Adjusted Performance of (0.02), standard deviation of 5.42, and insignificant Risk Adjusted Performance. Ginkgo Bioworks technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.Ginkgo Bioworks' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ginkgo Bioworks insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ginkgo Bioworks' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Ginkgo Bioworks insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Ginkgo Bioworks' Outstanding Corporate Bonds
Ginkgo Bioworks issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Ginkgo Bioworks Holdings uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Ginkgo bonds can be classified according to their maturity, which is the date when Ginkgo Bioworks Holdings has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Dana 575 percent Corp BondUS235822AB96 | View | |
Volcan Compania Minera Corp BondUSP98047AC08 | View | |
Boeing Co 2196 Corp BondUS097023DG73 | View | |
HSBC Holdings PLC Corp BondUS404280DR76 | View | |
MPLX LP 4875 Corp BondUS55336VAG59 | View | |
MPLX LP 4125 Corp BondUS55336VAK61 | View | |
MPLX LP 52 Corp BondUS55336VAL45 | View | |
International Game Technology Corp BondUS460599AD57 | View |
Understand Ginkgo Bioworks' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Ginkgo Bioworks' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
Risk Adjusted Performance | (0) | |||
Market Risk Adjusted Performance | (0.02) | |||
Mean Deviation | 4.12 | |||
Coefficient Of Variation | (7,486) | |||
Standard Deviation | 5.42 | |||
Variance | 29.34 | |||
Information Ratio | (0.04) | |||
Jensen Alpha | (0.39) | |||
Total Risk Alpha | (0.94) | |||
Treynor Ratio | (0.03) | |||
Maximum Drawdown | 27.15 | |||
Value At Risk | (9.23) | |||
Potential Upside | 8.95 | |||
Skewness | (0.36) | |||
Kurtosis | 0.4792 |
Risk Adjusted Performance | (0) | |||
Market Risk Adjusted Performance | (0.02) | |||
Mean Deviation | 4.12 | |||
Coefficient Of Variation | (7,486) | |||
Standard Deviation | 5.42 | |||
Variance | 29.34 | |||
Information Ratio | (0.04) | |||
Jensen Alpha | (0.39) | |||
Total Risk Alpha | (0.94) | |||
Treynor Ratio | (0.03) | |||
Maximum Drawdown | 27.15 | |||
Value At Risk | (9.23) | |||
Potential Upside | 8.95 | |||
Skewness | (0.36) | |||
Kurtosis | 0.4792 |
Consider Ginkgo Bioworks' intraday indicators
Ginkgo Bioworks intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Ginkgo Bioworks stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Ginkgo Bioworks Corporate Filings
F4 | 22nd of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
F3 | 8th of November 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
12th of September 2024 Other Reports | ViewVerify |
Ginkgo Stock media impact
Far too much social signal, news, headlines, and media speculation about Ginkgo Bioworks that are available to investors today. That information is available publicly through Ginkgo media outlets and privately through word of mouth or via Ginkgo internal channels. However, regardless of the origin, that massive amount of Ginkgo data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Ginkgo Bioworks news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Ginkgo Bioworks relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Ginkgo Bioworks' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Ginkgo Bioworks alpha.
Ginkgo Bioworks Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Ginkgo Bioworks can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Ginkgo Bioworks Holdings Historical Investor Sentiment
Investor biases related to Ginkgo Bioworks' public news can be used to forecast risks associated with an investment in Ginkgo. The trend in average sentiment can be used to explain how an investor holding Ginkgo can time the market purely based on public headlines and social activities around Ginkgo Bioworks Holdings. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Ginkgo Bioworks' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Ginkgo Bioworks and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Ginkgo Bioworks news discussions. The higher the estimate score, the more favorable the investor's outlook on Ginkgo Bioworks.
Ginkgo Bioworks Corporate Management
Anna Wagner | Senior Development | Profile | |
Samantha Sutton | Head People | Profile | |
Joaquim Marques | Head Chemistry | Profile | |
Mark Dmytruk | Chief Officer | Profile | |
Reshma Shetty | President, Founder | Profile | |
Joshua Dunn | Head Design | Profile | |
Thomas Knight | Founder | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Ginkgo Bioworks Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ginkgo Bioworks. If investors know Ginkgo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ginkgo Bioworks listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (12.89) | Revenue Per Share 4.291 | Quarterly Revenue Growth 0.606 | Return On Assets (0.21) | Return On Equity (0.64) |
The market value of Ginkgo Bioworks Holdings is measured differently than its book value, which is the value of Ginkgo that is recorded on the company's balance sheet. Investors also form their own opinion of Ginkgo Bioworks' value that differs from its market value or its book value, called intrinsic value, which is Ginkgo Bioworks' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ginkgo Bioworks' market value can be influenced by many factors that don't directly affect Ginkgo Bioworks' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Ginkgo Bioworks' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Ginkgo Bioworks is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ginkgo Bioworks' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.